Stage IIIA Ovarian Cancer Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Stage IIIA Ovarian Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Early Phase 1

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Stage III Ovarian Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IIIA Ovarian Cancer AJCC v8+30 more
Ohio State University Comprehensive Cancer Center45 enrolled1 locationNCT05415709
Recruiting
Phase 1

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+71 more
M.D. Anderson Cancer Center43 enrolled1 locationNCT05092373
Recruiting

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

Malignant Brain NeoplasmMalignant Solid NeoplasmMalignant Testicular Neoplasm+97 more
University of Southern California250 enrolled1 locationNCT07259304
Recruiting
Phase 1

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Stage IIIA Uterine Corpus Cancer AJCC v8+35 more
M.D. Anderson Cancer Center54 enrolled1 locationNCT05039801
Recruiting

Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer

Ovarian NeoplasmsStage III Ovarian Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8+12 more
Massachusetts General Hospital250 enrolled6 locationsNCT04794322
Recruiting
Phase 2

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

Metastatic Malignant Solid NeoplasmRecurrent Ovarian CarcinomaStage III Ovarian Cancer AJCC v8+17 more
Rutgers, The State University of New Jersey40 enrolled2 locationsNCT03428802
Recruiting

Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer

Stage IV Ovarian CancerStage IIIA Ovarian CancerStage IIIB Ovarian Cancer+1 more
Gynecologic Oncology Group174 enrolled1 locationNCT01000259